An antitumor nanocluster based on a dynamic combinatorial molecular library, its preparation method and applications

By constructing a dynamic combinatorial molecular library based on the template molecule C18-D3.0 and the module molecule 3,5-dimercaptobenzoic acid, antitumor nanomicelles were prepared. This solved the problem of insufficient regularity in the research of antitumor nanoclusters using dynamic combinatorial molecular libraries in the prior art. It achieved deep drug penetration and targeted release at the tumor site, significantly improved the antitumor effect and reduced toxic side effects.

CN122461476BActive Publication Date: 2026-11-17ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202610912360.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-06-24
Publication Date
2026-11-17
Estimated Expiration
2046-06-24

AI Technical Summary

Technical Problem

Existing research on antitumor nanoclusters based on dynamic combination molecular libraries in chemical drug delivery systems lacks regularity, the effects are unpredictable, and traditional nanocarrier design is time-consuming and costly.

Method used

A dynamic combinatorial molecular library was constructed using template molecules C18-D3.0 and/or 2C18-D3.0 and module molecules such as 3,5-dimercaptobenzoic acid to prepare antitumor nanomicelles. The thiol groups of the module molecules were deprotonated and oxidized into rings at physiological pH to form a dynamic combinatorial molecular library, thereby improving the drug's targeting and sustained-release effect.

Benefits of technology

This technology enables deep penetration and drug release of anti-tumor nanoclusters at the tumor site, improving drug targeting, reducing toxic side effects, and significantly enhancing anti-tumor efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122461476B_ABST
    Figure CN122461476B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of drug carrier technology, specifically relating to an antitumor nanocluster based on a dynamically combinatorial molecular library, its preparation method, and its applications. This antitumor nanocluster uses specific template molecules to load antitumor drugs into drug-loaded nanomicelles, which are then combined with disulfide-bonded modular molecules to form an antitumor nanocluster based on a dynamically combinatorial molecular library. This significantly improves the tumor tissue targeting of antitumor drugs, reduces their side effects, and enhances antitumor activity, achieving unexpected antitumor effects in animal experiments.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of nanomedicine carrier technology, specifically relating to an antitumor nanocluster based on a dynamically combined molecular library, its preparation method, and its uses. Background Technology

[0002] Chemotherapy is a routine treatment for cancer. To overcome the side effects caused by poor targeting of chemotherapy drugs, nanoparticles are commonly used in this field to improve drug targeting while also providing a certain degree of sustained release. These nanoparticles typically use polymers with specific structures as carriers. For example, in patent document CN117919437A, a modified PAMAM dendritic macromolecule is combined with the natural antitumor active ingredient of *Echinochloa crus-galli* alkaloids to construct a dendritic drug-loaded complex. In patent document CN108245483A, amphiphilic polymers with hydrophobic hinges of polyethylene glycol (mPEG) and polylactic acid (PLA) of different chain lengths are used as carriers to encapsulate the hydrophobic drug paclitaxel to obtain nanomicelles. In conventional nanoparticle carrier design schemes, the formulation of self-assembly strategies and the structure of amphiphilic molecules rely on artificial design and are selected from many candidate molecules. This process is very time-consuming and makes it difficult to obtain the optimal solution, which is an extremely costly and inefficient process for traditional covalent synthesis chemistry.

[0003] Nature typically generates functional molecules at the system level, rather than through inefficient synthetic processes. Molecules in living systems evolve by responding to and adapting to changes in their natural environment. Natural selection incorporates error-correction mechanisms into the synthetic process, enabling selected molecules to highly adapt to their environment and its dynamic changes. Dynamic combinatorial chemistry shares similar synthetic principles with nature. It utilizes modular molecules capable of reversible covalent reactions to construct dynamic combinatorial libraries (DCLs) in a combinatorial manner. This allows for a modular, systematic, and dynamic synthetic process with closed-loop, self-feedback-regulated behavior, where the concentration distribution of library members is typically in thermodynamic equilibrium. As DCLs recombine library members to adapt to changes within the system, the final nanostructure of the self-assembled DCL also undergoes an adaptive change, transforming from a binary nanonetwork structure to a ternary high aspect ratio nanorod structure.

[0004] Currently, antitumor nanoclusters based on dynamic combinatorial libraries are typically composed of building blocks (BBs), templates (Ts), and antitumor drugs. Among them, building blocks, for example, provide a doxorubicin (DOX)-loaded antitumor drug prepared using dimercaptobenzoic acid (meta) as a template molecule and pyridine with long-chain substituents as a template molecule, with a sustained release time of up to 13 days.

[0005] However, while this DCL-based strategy has been widely used in high-throughput drug screening (e.g. for discovering and screening specific ligand molecules), research on chemical drug delivery systems is still extremely limited and lacks regularity. The effects of antitumor nanoclusters based on dynamically combined molecular libraries are unpredictable (thermodynamic equilibrium behavior, drug distribution, stepwise degradation, and other behaviors are extremely complex). Summary of the Invention

[0006] To address the aforementioned problems, the purpose of this invention is to provide an antitumor nanocluster based on a dynamically combined molecular library, its preparation method, and its applications. The technical solution of this invention is as follows:

[0007] An antitumor nanocluster based on a dynamic combinatorial molecular library, wherein the antitumor nanocluster is made by a dynamic combinatorial molecular library formed by template molecules, drug-loaded nanomicelles made of antitumor drugs, and module molecules, wherein the template molecules are selected from C18-D3.0 and / or 2C18-D3.0.

[0008] , ;

[0009] C18-D3.0 and 2C18-D3.0 are compounds already disclosed in the prior art, and can be found in the literature:

[0010] [1] Chen C, Posocco P, Liu X, et al. Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In VivoEfficient Gene Silencing[J]. Small 2016,12(27), 3667-76.

[0011] [2] Wei T, Chen C, Liu J, et al. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance[J]. P. Natl. Acad. Sci. USA, 2015, 112(10), 2978-2983.

[0012] Preferably, the module molecule is selected from at least one of 3,5-dimercaptobenzoic acid, 2,5-dimercaptoterephthalic acid, 2,5-bis(mercaptomethyl)terephthalic acid, 3,5-bis(mercaptomethyl)benzoic acid, and 3-mercapto-3'-methyl[1,1'-biphenyl]-4,4'-dicarboxylic acid. The structural formulas of 3,5-dimercaptobenzoic acid, 2,5-dimercaptoterephthalic acid, 2,5-bis(mercaptomethyl)terephthalic acid, 3,5-bis(mercaptomethyl)benzoic acid, and 3-mercapto-3'-methyl[1,1'-biphenyl]-4,4'-dicarboxylic acid are as follows, and are hereinafter referred to as BB1-BB5 respectively.

[0013]

[0014] As an important component of dynamic combinatorial libraries (DCLs), the aforementioned building block (BB) contains carboxylic acid groups and thiol groups, which can be deprotonated at physiological pH. After deprotonation, its thiol group (also known as a thiol group) exhibits the reaction property of oxidizing and forming a ring via a disulfide bond under specific conditions (Cao Y, Yang J, Eichin D, et al. Self-Synthesizing Nanorods from Dynamic Combinatorial Libraries against Drug Resistant Cancer[J]. Angew Chem Int EdEngl. 2021, 60(6), 3062-3070.). The specific mechanism is shown in the following reaction formula:

[0015]

[0016] Preferably, the loaded antitumor drug is doxorubicin or a pharmaceutically acceptable salt thereof.

[0017] Preferably, in the antitumor nanoclusters, the molar ratio of module molecules to template molecules is <2. More preferably, in the antitumor nanoclusters, the molar ratio of module molecules to template molecules is ≤1.

[0018] Preferably, the molar ratio of template molecules to the loaded antitumor drug in the drug-loaded nanomicelles is (3.2~8.2):5.5. More preferably, the molar ratio of template molecules to the loaded antitumor drug in the drug-loaded nanomicelles is (3.2~4.4):5.5.

[0019] The aforementioned method for preparing antitumor nanoclusters includes the following steps:

[0020] Preparation of S1 drug-loaded nanomicelles: Template molecules and loaded antitumor drugs were dissolved in an organic solvent to obtain a template molecule-drug mixture, and drug-loaded nanomicelles were prepared by ultrasound-thin film method.

[0021] S2 module molecule processing: Take the module molecule, add buffer solution to deprotonate the module molecule, and oscillate to oxidize the free thiol groups to obtain the module molecule pretreatment solution;

[0022] Preparation of S3 antitumor nanoclusters: The drug-loaded nanomicelles obtained in step S1 were pre-cooled, injected into the module molecule pretreatment solution obtained in step S2, and subjected to ultrasonic treatment and then allowed to stand to obtain antitumor nanoclusters.

[0023] Preferably, in step S2, the oscillation reaction oxidizes the free thiol groups to a concentration below 10 μM; and in step S3, the settling time after ultrasonic treatment is ≥3 h. More preferably, the settling time after ultrasonic treatment in step S3 is 3 h to 48 h.

[0024] Preferably, the ultrasound-thin-film method in step S1 includes: sonicating the template molecule-drug mixture at 100W~800W power for 5min~30min, then removing the organic reagent by rotary evaporation at 20℃~40℃, then adding buffer solution and sonicating at 100W~800W power for 10min~30min, then incubating at 40℃~70℃ for 30min~60min, followed by dialysis after microporous membrane filtration; the buffer solution is preferably phosphate buffer. More preferably, the dialysis bag used for dialysis has a molecular weight cutoff of 8000Da~14000Da.

[0025] Preferably, in step S2, the pH of the buffer solution is 7-8, and the concentration of module molecules in the buffer solution is 3mM-12mM; the buffer solution is preferably a phosphate buffer solution.

[0026] Preferably, in step S3, the drug-loaded nanomicelles are pre-cooled to a temperature of 0℃~4℃ before being injected into the module molecule pretreatment solution obtained in step S2. More preferably, in step S3, the ultrasonic conditions are ultrasonic power of 300W~800W and ultrasonic time of 20min~60min; even more preferably, in step S3, the post-ultrasonic settling condition is settling at room temperature.

[0027] The aforementioned antitumor nanoclusters are used in the preparation of targeted antitumor drugs.

[0028] Beneficial effects:

[0029] The antitumor nanoclusters of this invention utilize C18-D3.0 and / or 2C18-D3.0 as template molecules to load antitumor drugs as drug-loaded nanomicelles, which are then combined with the template molecules to construct DCLs. The resulting antitumor nanoclusters can target tumor tissues using high permeability and retention effects (EPR effect), and release nanoparticles in response to stimulation in the tumor microenvironment (GSH and microacidity), achieving deep penetration and drug delivery of nanomedicines to the tumor site. This improves the targeting of antitumor drugs, thereby enhancing efficacy and reducing toxic side effects. Compared with existing doxorubicin DCL antitumor nanorods, the antitumor effect is unexpectedly improved. Attached Figure Description

[0030] Figure 1 Comparison of transmission electron microscopy images of antitumor nanoclusters with different R values ​​prepared in Example 2;

[0031] Figure 2Comparison of transmission electron microscope images of antitumor nanoclusters prepared at different temperatures in Example 2;

[0032] Figure 3 Comparison of transmission electron microscope images of antitumor nanoclusters prepared for different standing times in Example 2;

[0033] Figure 4 Comparison of transmission electron microscope images of antitumor nanoclusters prepared from non-thiol module molecules (a) benzoic acid, (b) terephthalic acid, and (c) 4,4'-biphenyldicarboxylic acid in Example 2;

[0034] Figure 5 The figures show (a) in vivo animal imaging and (b) the statistical results of the proportion of microvessels in Example 3;

[0035] Figure 6 The images shown in Example 4 are: (a) fluorescence detection results of different test substances distributed in Panc02 tumor-bearing mice, (b) comparison of fluorescence signal intensity in different organs, (c) fluorescence detection results of different organs at different time points, and (d) analysis results of nano-fluorescence intensity in ex vivo tumors at different time points.

[0036] Figure 7 This is a fluorescence detection result of the distribution of different test substances in Hepa1-6 tumor-bearing mice in Example 4;

[0037] Figure 8 The results are shown in Example 5: (a) tumor volume, (b) body weight, and (c) tumor photograph and tumor weight result graph. Detailed Implementation

[0038] The present invention and its effects are further illustrated below with reference to specific embodiments and accompanying drawings. It should be understood that these embodiments are only used to demonstrate the implementation methods and effects of the present invention and are not intended to limit the scope of protection of the present invention. After reading the contents of this invention, those skilled in the art can make various simple modifications or alterations to the present invention without creative effort, and these equivalent / identical transformations also fall within the scope of protection of the present invention. In the following embodiments, room temperature refers to 10℃~30℃.

[0039] Example 1: Preparation of doxorubicin-loaded nanomicelles (using template molecules and doxorubicin)

[0040] In this embodiment, 2C18-D3.0 was used as the template molecule (T), and doxorubicin (DOX) was used as the model antitumor drug to prepare DOX-loaded 2C18-D3.0 nanomicelles. 2C18-D3.0 was prepared using a method already published in the literature: see: Wei T, Chen C, Liu J, et al. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance[J]. P.Natl. Acad. Sci. USA, 2015, 112(10), 2978-2983. The structural formula of 2C18-D3.0 is as follows:

[0041]

[0042] DOX-loaded micelles were prepared using an ultrasonic-thin film method: 15 mg (5.2 mmol) of 2C18-D3.0 and 3 mg (5.5 mmol) of doxorubicin were weighed and dissolved together in a mixed solvent of methanol and dichloromethane (1.5 ml of methanol and 1 ml of dichloromethane). The mixture was ultrasonicated at 400 W for 10 min, then transferred to a constant temperature water bath at 28 °C, and the organic reagents were removed by vacuum rotary evaporation at 480 rpm until a uniform and transparent film formed on the flask wall. Subsequently, 4.8 ml of 2.5 mM phosphate-buffered saline (PBS, pH 7.4) was added, and the mixture was ultrasonicated at 400 W for 15 min, followed by incubation at 60 °C with stirring for 40 min. After the reaction was complete, the solution was filtered through a 0.22 μm microporous membrane and dialyzed in a dialysis band with a molecular weight cutoff of 8000 Da (the molecular weight cutoff can be between 8000 Da and 14000 Da; 8000 Da was chosen here) to obtain a T / DOX nanomicelle solution system (hereinafter referred to as the T / DOX system). The concentrations of DOX and template T in the PBS solution obtained after dialysis were 1.149 mM and 0.725 mM, respectively.

[0043] The concentrations of DOX and T in the T / DOX system were determined using HPLC. The specific detection methods are as follows: all analyses were performed using HPLC (Hypersilicon). TMThe experiment was performed using an ODS C18 reversed-phase column (5 μm particle size, 4.6 mm inner diameter, 250 mm length). UV absorbance was measured at 254 nm, and the column temperature was maintained at 25℃. Sample pretreatment: After dialysis, 0.1 mL of the solution was diluted to 3 mL with methanol, and 10 μL was injected after ultrasonic demulsification. Establishment of the standard curve: DOX methanol standard solutions with concentrations of 0.5, 1, 2, 5, and 10 μg / mL were prepared. 10 μL of each standard solution was precisely injected into the HPLC system. Linear regression was performed with DOX concentration (c, μg / mL) as the abscissa and peak area (A) as the ordinate, yielding the linear regression equation A = 36745c - 12818 (R²). 2 =0.998). Injection volume: 10 μL, eluent A: water, eluent B: HPLC grade acetonitrile. Eluent flow rate: 1.0 mL / min, elution program is shown in Table 1.

[0044] Table 1 Mobile phase elution procedure

[0045] The final measured concentrations of DOX and template T were 1.149 mM and 0.725 mM, respectively.

[0046] Example 2: Preparation of DOX-loaded nanoclusters based on DCL (prepared using DOX-loaded nanomicelles and modular DCL molecules)

[0047] (1) Construction of module molecular pretreatment solution

[0048] 2,5-Dimercaptoterephthalic acid (BB2) was selected as the module molecule for constructing a dynamic combinatorial library (DCL). 50 mg of BB2 was accurately weighed and dissolved in PBS to prepare a 5.43 mM BB2 preparative solution (pH 7.4), deprotonating the carboxyl and thiol groups of BB2. The preparative solution was then agitated at room temperature to oxidize the free thiol groups, yielding the module molecule pretreatment solution. Free thiol groups were detected using HPLC. Specific detection methods are as follows: All analyses were performed using HPLC (Hypersilicon). TM The experiment was conducted using an ODSC18 reversed-phase column (5 μm particle size, 4.6 mm inner diameter, 250 mm length), with UV absorbance measured at 254 nm and the column temperature maintained at 25 °C. 10 μL of the prepared module molecule pretreatment solution was injected, and the mobile phase and elution procedure were consistent with those in Example 1.

[0049] (2) Preparation and analysis of DCL-based DOX-loaded nanoclusters

[0050] The T / DOX system (i.e., the nanomicelle solution system) was prepared using the method of Example 1; the module molecule pretreatment solution was prepared using the method of step (1) of this example.

[0051] First, the T / DOX system was pre-cooled to 4°C for 10 minutes to reach equilibrium. Then, while maintaining this temperature, different proportions of BB2 module molecule pretreatment solutions were injected into the T / DOX system. Next, the mixture was sonicated at 600 W for 40 minutes (temperature 20°C~40°C is acceptable; here, 30°C was chosen for sonication) to promote molecular movement and achieve assembly equilibrium. The reaction system was then placed at room temperature for 3 hours to promote the formation of a multipolymer chemical library, resulting in T / DOX / BB2 nanoclusters. The molar ratio R of module molecules to template molecules in the nanoclusters was calculated using the formula R=C1V1 / C2V2 (where C1 and V1 are the concentrations of module molecules in the module molecule pretreatment solution before mixing and the volume of the module molecule pretreatment solution used in mixing, and C2 and V2 are the concentrations of template molecules in the T / DOX system before mixing and the volume of the T / DOX system used in mixing). In the T / DOX system before mixing, the concentrations of DOX and template T were 1.149 mM and 0.725 mM, respectively; the concentration of module molecule BB2 in the module molecule pretreatment solution before mixing was 5.43 mM. The change in R value was obtained by changing the volume of the T / DOX system and the module molecule pretreatment solution used during mixing. Figure 1 Transmission electron microscopy (TEM) images of antitumor nanoclusters with different R values ​​prepared using this method. It can be seen that when the R value ≥ 2 ( Figure 1 The left-hand figure shows nanoclusters with R≥2 (the exact value of R is 2), forming a grape-like nanocluster structure with a size greater than 200 nm; when the R value is between 1 and 2 ( Figure 1 The middle figure shows a nanocluster with R=1.2, forming a rod-like structure with a size of approximately 70nm~200nm; when R value ≤1 ( Figure 1 The right-hand side of the figure shows a nanocluster with R=0.8, which forms a garnet-like spherical structure of approximately 50nm~80nm. This demonstrates that the R value significantly affects the self-assembly characteristics of nanoclusters.

[0052] To further investigate the effects of other influencing factors on anti-tumor nanoclusters, the following exploratory examples (R value of 0.8 for all) were prepared according to this method for investigation and comparison:

[0053] 1) Using the same method, the effects of pre-cooling the T / DOX system to 0-4℃ (ice bath), 15℃, and 25℃ before adding the BB2 module molecular pretreatment solution on the anti-tumor nanoclusters were investigated by changing the pre-cooling temperature of the T / DOX system (other steps and process parameters remained unchanged). TEM images are shown below. Figure 2As shown, when the precooling temperature of the T / DOX system gradually increases, the garnet-state nanoclusters gradually aggregate. When the temperature reaches 25℃, the aggregation effect is very obvious, and a large number of nanoclusters can be seen sticking together head to tail to form larger and more irregular morphologies. Therefore, 0~4℃ (ice bath) is the optimal temperature for preparing these nanoclusters.

[0054] 2) Using the same method, the effect of the settling time after mixing the T / DOX system with the BB2 module molecular pretreatment solution and sonicating at room temperature (4h, 48h) was investigated on the anti-tumor nanoclusters (other steps and process parameters remained unchanged). The results are as follows: Figure 3 As shown, standing for 4 h and 48 h had no significant effect on the morphology of the nanoclusters, indicating that the nanoclusters prepared when R < 1 had good stability and no significant change in morphology was observed after 48 h.

[0055] 3) Using the same method, the effects of mercapto-free module molecules (a: benzoic acid; b: terephthalic acid; c: 4,4'-biphenyl dicarboxylic acid) on the antitumor nanoclusters were investigated by changing the module molecules (the module molecule pretreatment solution was shaken and vibrated at room temperature for 12 h before being mixed with the T / DOX system, with other steps and process parameters remaining unchanged). The results are as follows: Figure 4 As shown, when the module molecules are changed to benzoic acid (a), terephthalic acid (b), and 4,4'-biphenyl dicarboxylic acid (c), the resulting structures are all irregular and amorphous nano or micro structures, which cannot meet the requirements for use.

[0056] The above studies show that the R-value, the pre-cooling temperature of the T / DOX system, and the module molecules all affect the self-assembly characteristics of nanoclusters. Among them, the best results are achieved with an R-value ≤ 1, a T / DOX system pre-cooling temperature of 0~4℃ (ice bath), and 2,5-dimercapto-terephthalic acid as the module molecule.

[0057] Example 3: Mouse Tumor Angiography

[0058] This embodiment uses the T / DOX system (i.e., the nanomicelle solution system, in which the DOX concentration is 1.149 mmol / L and the template molecule T concentration is 0.725 mM) prepared according to Example 1 and the nanoclusters prepared according to Example 2 (the concentrations of DOX and template T in the T / DOX system before mixing are 1.149 mM and 0.725 mM, respectively; the T / DOX system is pre-cooled to 4°C for 10 min before adding the module molecule pretreatment solution, mixed and sonicated, and then placed at room temperature for 3 h; the concentration of module molecule BB2 in the module molecule pretreatment solution before mixing is 5.43 mM; the R value of the nanoclusters is 0.8) as the research object for in vivo animal imaging investigation.

[0059] Seven-week-old male C57bl / 6 mice inoculated with Hepa1-6 (a mouse hepatocellular carcinoma cell line, a tumor model characterized by high vascular density) were randomly divided into three groups (n=3). The tumor volume in each group was approximately 100±10 mm. 3 Two hours after the last tail vein injection, mice were anesthetized with urethane via intraperitoneal injection, followed by tail vein injection of sulfur hexafluoride microbubbles. The changes in microvessel density distribution in the nano-formulation group after tumor treatment were detected using a super-resolution small animal ultrasound imaging system. Group 1 was the PBS group, with tail vein injection of PBS at pH 7.4. Group 2 was the T / DOX group, with tail vein injection of the T / DOX system prepared according to Example 1; Group 3 was the T / DOX / BB2 nanocluster group, with tail vein injection of anti-tumor nanoclusters prepared according to Example 2. Before administration, the concentrations of the T / DOX system and T / DOX / BB2 nanoclusters were adjusted using PBS (pH 7.4) to ensure equal DOX concentrations. The dosage per mouse in each treatment group was 5 mg / kg body weight, administered every other day for a total of 7 doses (based on DOX).

[0060] like Figure 5 As shown, after treating tumor-bearing mice with control and formulation groups respectively, super-resolution microscopy revealed that the microvascular density in the tumor site of the T / DOX / BB2 group was significantly lower than that of the other two groups. This indicates that the stepwise delivery of nanoclusters by T / DOX / BB2 has a significant remodeling function on the tumor microvascular environment.

[0061] Example 4: Study on the targeted distribution of drugs in vivo

[0062] Animals: Seven-week-old male C57bl / 6 mice, weighing 18-22g, were selected.

[0063] Models: Panc02 and Hepa1-6 cell line tumor models were selected. Panc02 is characterized by low permeability and high invasiveness; after subcutaneous transplantation, it not only forms rapidly enlarging solid tumors locally but also shows significant metastatic lesions in the liver and occasionally spreads to the lungs. It is an effective preclinical model for the invasion and drug resistance behavior of human pancreatic cancer. The Hepa1-6 tumor model is characterized by high vascular density and is widely used for tumor angiography, angiogenesis mechanism research, and anti-angiogenic drug evaluation.

[0064] Cells, treatment, and seeding: Panc02 cells in logarithmic growth phase were collected and a cell suspension was prepared with a density of 1×10⁻⁶ cells / mL. 7 Cells / ml. Inject 100 μl of the cell suspension into the right axilla of each mouse. On the day of inoculation, closely monitor the mice's condition and record their weight. The Hepa1-6 cells, treatment, and inoculation methods are the same as those for the Panc02 cells described above.

[0065] Preparation of T / DiR nanomicelles: Accurately weigh 10 mg of 2C18-D3.0 (T) and dissolve it in 1.0 mL of a mixed solution of dichloromethane and methanol (volume ratio of dichloromethane to methanol: 1:2). Add 1 mg of DiR (DiR is a lipophilic, near-infrared fluorescent anthocyanin dye) to the above mixed solution, remove the organic solvent by rotary evaporation, and obtain a dry film. Add 2.5 mM PBS, sonicate for 15 min, stir at 100 rpm for 40 min at 60 °C, dialyze, and filter.

[0066] Preparation of T / DiR / BB2, T' / DiR / BB1 nanoclusters and rods: The T / DiR prepared above was then introduced into a dynamic combinatorial chemistry library with BB2 as the building block. The final concentrations of the template T and the module molecule BB2 were 0.356 mM and 0.284 mM, respectively, and T / DiR / BB2 nanoclusters were prepared under ultrasonic ice bath conditions. T' / DiR / BB1 (the module molecule BB1 ​​was 3,5-dimercaptobenzoic acid) was prepared according to the method in the literature (Cao Y, Yang J, Eichin D, et al. Self-Synthesizing Nanods from Dynamic Combinatorial Libraries against Drug Resistant Cancer[J]. Angew Chem Int Ed Engl. 2021;60(6), 3062-3070.), except that DOX was replaced with DiR. The concentrations of the template T' and the module molecule BB1 ​​were 0.483 mM and 5.43 mM, respectively.

[0067] In vivo and in vitro imaging and immunofluorescence in mice: To investigate the biological distribution of nanoclusters and rods in male Panc02 tumor-bearing C57BL / 6 mice, 200 μl of DiR, T' / DiR / BB1, and T / DiR / BB2 formulations (n=3 per group) were injected via the tail vein at a dose equivalent to 0.2 mg / ml DiR. In vivo biodistribution was assessed using an imaging system to monitor the distribution of T' / DiR / BB1 nanorods and T / DiR / BB2 nanoclusters in mice, and immunofluorescence analysis was performed on tumors and major organs. Hepa1-6 tumor-bearing male C57BL / 6 mice were treated in the same manner as the Panc02 tumor-bearing male C57BL / 6 mice described above.

[0068] Biodistribution experiments using nanocarriers loaded with the fluorescent dye DiR further confirmed that T / DiR / BB2 nanoclusters, due to their size advantage, can target and be rapidly captured to tumor tissues through the EPR effect. Stimulated by the tumor microenvironment, they release small-sized nanomicelles of T / DiR, which can better penetrate the tumor barrier and enter the cell nucleus, achieving effective drug accumulation and retention. Figure 6 The in vivo biological distribution of the Panc02 tumor cell line model. For example... Figure 6 As shown in a and c, within 3–6 hours after injection of the fluorescent dye, T / DiR / BB2 can enter the tumor site more rapidly than T' / DiR / BB1. Simultaneously, from… Figure 6 As shown in b, around 24 hours later, the fluorescence intensity of the tumor was much higher than that of other organs. Figure 6 The 'c' indicates that the nanocarrier maximizes tumor accumulation around 24 hours and continues until 48 hours. The fluorescence intensity at the tumor site remains at a high level, which may indicate that the nanoclusters release smaller nanomicelles in the tumor, allowing the fluorescent dye to reach the tumor more effectively and accumulate. Figure 6 The results further confirm that T / DiR / BB2 nanoclusters, due to their size advantage (50nm-80nm), can target tumor tissues through the EPR effect and be rapidly captured. Stimulated by the tumor microenvironment, they release small-sized T / DiR nanoparticles, which can better penetrate the tumor barrier and enter the cell nucleus, achieving effective drug accumulation and retention. Figure 7 The image shows the fluorescence detection results of different test substances distributed in Hepa1-6 tumor-bearing mice. T / DiR / BB2 entered the tumor site more rapidly than DiR and T' / DiR / BB1, and the fluorescence intensity in the tumor was significantly higher than in other organs. This indicates that nanoclusters can significantly improve the tumor targeting of DiR, promoting the release of drug-loaded nanoparticles, specifically targeting and accumulating within the tumor. Furthermore, at 48 hours, only T / DiR / BB2 still showed significant fluorescence intensity at the tumor site, indicating that T / DiR / BB2 accumulated for a longer time, reduced the drug metabolism rate, and enhanced the duration of efficacy at the tumor site.

[0069] Example 5: Animal Antitumor Efficacy Experiment

[0070] Animals: Seven-week-old male C57bl / 6 mice, weighing 18-22g, were selected.

[0071] Cells, treatment, and seeding: Hepa1-6 cells in logarithmic growth phase were collected and prepared into a cell suspension with a density of 1×10⁻⁶. 7 Cells / ml. Inject 100 μl of the cell suspension into the right axilla of each mouse. On the day of inoculation, closely monitor the mice's condition and record their weight.

[0072] Samples and Preparation: Test samples included PBS (pH 7.4, as a negative control), DOX (as a positive control), T / DOX group (T / DOX system prepared according to Example 1, with DOX and template T concentrations of 1.149 mM and 0.725 mM, respectively), T / DOX / BB2 antitumor nanocluster group A (prepared according to Example 2, with DOX and template T concentrations of 1.149 mM and 0.725 mM, respectively, in the T / DOX system before mixing; the T / DOX system was pre-cooled to 4°C for 10 min before adding the module molecule pretreatment solution, mixed and sonicated, and then placed at room temperature for 3 h; the module molecule BB2 concentration in the module molecule pretreatment solution before mixing was 5.43 mM; nanocluster R value = 0.8), and T / DOX / BB2 antitumor nanocluster group B (prepared according to Example 2, with DOX and template T concentrations of 1.149 mM and 0.725 mM, respectively, in the T / DOX system before mixing). The concentrations of DOX and template T in system X were 1.149 mM and 0.725 mM, respectively. The T / DOX system was pre-cooled to 4°C for 10 min before adding the module molecule pretreatment solution, mixed, and sonicated before being placed at room temperature for 3 h. The concentration of module molecule BB2 in the module molecule pretreatment solution before mixing was 5.43 mM. The R value of the nanocluster was 1.2. The T / DOX / BB2 anti-tumor nanocluster group C (prepared according to Example 2, the concentrations of DOX and template T in the T / DOX system before mixing were 1.149 mM and 0.725 mM, respectively; the T / DOX system was pre-cooled to 4°C for 10 min before adding the module molecule pretreatment solution, mixed, and sonicated before being placed at room temperature for 3 h. The concentration of module molecule BB2 in the module molecule pretreatment solution before mixing was 5.43 mM. The R value of the nanocluster was 2.) and the T' / DOX / BB1 anti-tumor nanocluster group.

[0073] The T' / DOX / BB1 antitumor nanoclusters were prepared according to the method described in the literature (Cao Y, Yang J, Eichin D, et al. Self-Synthesizing Nanorods from Dynamic Combinatorial Libraries against Drug Resistant Cancer[J]. Angew Chem Int Ed Engl. 2021;60(6), 3062-3070.), using 3,5-dimercaptobenzoic acid (i.e., BB1) as the module molecule and a pyridine derivative as the template molecule (T', see the literature). Figure 1DOX was used as a model drug (prepared according to Example 2; the final concentrations of DOX and template T' in the T' / DOX system before mixing were 1.149 mM and 1.88 mM, respectively; the T' / DOX system was pre-cooled to 4°C for 10 min before adding the module molecule pretreatment solution, mixed, sonicated, and then placed at room temperature for 3 h; the final concentration of module molecule BB1 ​​in the module molecule pretreatment solution before mixing was 0.94 mM; the molar ratio of BB1 to T' was 2 / 1). Grouping and administration: Mice inoculated with tumor cells were randomly divided into 7 groups of 7 mice each on the second day after inoculation. They were given negative control, positive control, and different drug-loaded nanomicelles or anti-tumor nanoclusters via tail vein injection, respectively. The drugs were administered every other day, with the first administration recorded as day 0, and a total of 7 administrations were given. Before administration, the concentrations of the T / DOX system, T / DOX / BB2 nanoclusters, and T' / DOX / BB1 were adjusted using PBS (pH 7.4) to ensure equal DOX concentrations. The dosage per mouse in the administration group was 5 mg / kg body weight, calculated as DOX. The route of administration, administration volume, and single dose calculated as DOX were the same as in Example 3.

[0074] During drug administration, the mice's condition was closely monitored, including their mental state, activity level, water intake, and food consumption. Mice body weight and tumor volume were measured every other day, and corresponding curves showing changes in body weight and tumor size were plotted. The tumor volume was calculated using the formula: V = a × b 2 / 2 (mm 3 (V represents tumor volume, a represents the maximum diameter of the tumor, and b represents the shortest diameter of the tumor). Mice were sacrificed 24 hours after drug administration, and tumors were removed to determine tumor weight. Heart, liver, spleen, lung, and kidney sections were routinely prepared for pathological observation.

[0075] The results are as follows Figure 8 As shown, during treatment with the free drug (DOX group), the mice experienced a significant reduction in body weight compared to other treatment groups, and a large number of deaths occurred. Figure 8 a in Figure 8 The missing data on body weight and tumor volume after day 6 in the data are due to the mortality of all animals in that group; because of the mortality of that group, therefore Figure 8 (d in the figure was not included in the tumor weight comparison).

[0076] All animals in the T / DOX nanomicelle and antitumor nanocluster groups survived. The tumor volume and weight of the T / DOX / BB2 antitumor nanocluster group A (R=0.8≤1) were significantly lower than those of the nanomicelle and other antitumor nanocluster groups (p<0.01). Although the tumor volume and weight of the T / DOX / BB2 antitumor nanocluster group B (R=1.2) were slightly lower than those of the T' / DOX / BB1 group, there was no statistical difference. The tumor volume and weight of the T / DOX / BB2 antitumor nanocluster group C (R=2) were significantly higher than those of the T' / DOX / BB1 group, but there was no statistical difference compared with the T / DOX nanomicelle group. By comparing the tumor weight of each group with that of the PBS group, it was found that the tumor weights of the T / DOX group, T / DOX / BB2 (R=0.8≤1), T / DOX / BB2 (R=1.2), and T / DOX / BB2 (R=2) groups were 0.24 times, 0.005 times, 0.068 times, and 0.34 times that of the PBS group, respectively.

[0077] Figure 8 In the diagram, 'c' represents the tumor images after each group of drugs were administered. 'X' indicates that the corresponding animal died before the end of drug administration, and circles represent tumors that disappeared by the end of drug administration and could not be dissected for measurement. It can be seen that in group A (R=0.8≤1), 6 / 7 of the tumors in mice of the T / DOX / BB2 anti-tumor nanocluster group disappeared, demonstrating stronger tumor inhibition and safety due to better targeting.

[0078] The above results indicate that the nanostructure effectively reduces the toxic side effects of doxorubicin, and the T / DOX / BB2 antitumor nanoclusters, especially when R=0.8≤1, can significantly improve the tumor targeting of DOX, promote the release of drug-loaded nanoparticles, specifically target and enter the tumor, and accumulate at the tumor site, thereby maximizing the antitumor therapeutic effect of the drug. This antitumor nanocluster not only effectively reduces the systemic toxicity of DOX and improves its biocompatibility and safety, but also overcomes the problems faced by traditional T / DOX small-sized nanoparticles in vivo, such as liver capture, rapid renal clearance, and non-specific adsorption of plasma proteins induced by cationic nanocarriers. Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions should not deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. An antitumor nanocluster based on a dynamic combinatorial library, characterized in that, The antitumor nanoclusters are made from a dynamic combination molecular library formed by template molecules, drug-loaded nanomicelles loaded with antitumor drugs, and module molecules. The template molecules are selected from C18-D3.0 and / or 2C18-D3.0 as described below. 、 ; The module molecule is 2,5-dimercaptoterephthalic acid; the loaded antitumor drug is doxorubicin or a pharmaceutically acceptable salt thereof; in the antitumor nanocluster, the molar ratio of the module molecule to the template molecule is ≤1. 2.The anti-tumor nanocluster based on dynamic combinatorial library of claim 1, wherein, The molar ratio of template molecules to loaded antitumor drugs in the drug-loaded nanomicelles is (3.2~8.2):5.

5. ​ 3. The method of claim 1, wherein the method is characterized in that, The preparation method includes the following steps: Preparation of S1 drug-loaded nanomicelles: Template molecules and loaded antitumor drugs were dissolved in an organic solvent to obtain a template molecule-drug mixture, and drug-loaded nanomicelles were prepared by ultrasound-thin film method. S2 module molecule processing: Take the module molecule, add buffer solution to deprotonate the module molecule, and oxidize it by shaking to obtain the module molecule pretreatment solution; Preparation of S3 antitumor nanoclusters: The drug-loaded nanomicelles obtained in step S1 were pre-cooled, injected into the module molecule pretreatment solution obtained in step S2, and subjected to ultrasonic treatment and then allowed to stand to obtain antitumor nanoclusters.

4. The method for preparing antitumor nanoclusters based on a dynamically combined molecular library according to claim 3, characterized in that, The ultrasound-thin film method described in step S1 includes: ultrasound of the template molecule-drug mixture at 100W~800W power for 5min~30min, followed by rotary evaporation at 20℃~40℃ to remove organic reagents, then adding buffer solution and ultrasound at 100W~800W power for 10min~30min, followed by incubation at 40℃~70℃ for 30min~60min, followed by filtration through a microporous membrane and dialysis.

5. The method according to claim 3, wherein the method comprises the following steps: 5.

1. synthesizing a dynamic combinatorial library (DCL) of anti-tumor nanoclusters; 5.

2. screening the DCL to obtain the anti-tumor nanoclusters; and 5.

3. purifying the anti-tumor nanoclusters. In step S2, the pH of the buffer solution is 7-8, and the concentration of module molecules in the buffer solution is 3mM-12mM.

6. The method for preparing antitumor nanoclusters based on a dynamically combined molecular library according to claim 3, characterized in that, In step S3, the drug-loaded nanomicelles are pre-cooled to a temperature of 0℃~4℃ and then injected into the module molecule pretreatment solution obtained in step S2.

7. The method for preparing antitumor nanoclusters based on a dynamically combined molecular library according to claim 3, characterized in that, In step S3, the ultrasonic conditions are ultrasonic power of 300W~800W and ultrasonic time of 20min~60min.

8. The use of the antitumor nanocluster based on a dynamic combinatorial molecular library as described in claim 1 or the antitumor nanocluster prepared by the preparation method described in claim 3 in the preparation of targeted antitumor drugs.

Citation Information

Patent Citations

  • Polymer nanometer micelle system loaded with slightly soluble antitumor drugs through coating

    CN108245483A

  • Dendrimer drug-loaded compound, preparation method and application thereof, pharmaceutical composition and application thereof

    CN117919437A

  • Preparation method and application of closed-loop feedback-regulation nano drug delivery system

    CN119607225A